Completed PHASE1 INTERVENTIONAL 2-arm NCT06969001

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Administration of SCAI-005 Ophthalmic Solution in Healthy Korean Subjects

Sponsor: SCAI Therapeutics

Conditions Wet Age Related Macular Degeneration

Interventions SCAI-005 0.04% or placebo SCAI-005 0.08% or placebo SCAI-005 0.08% or placebo 2drops

Updated 3 times since 2025 Last updated: Sep 7, 2025 Started: May 29, 2025 Primary completion: Sep 4, 2025 Completion: Sep 4, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Wet Age Related Macular Degeneration, this trial is completed. The trial is conducted by SCAI Therapeutics and has accumulated 3 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting
Jun 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

May 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SCAI Therapeutics

Data source: SCAI Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea